Literature DB >> 29195766

Dalbavancin is active in vitro against biofilms formed by dalbavancin-susceptible enterococci.

Katharina Neudorfer1, Suzannah M Schmidt-Malan1, Robin Patel2.   

Abstract

We tested the in vitro activity of dalbavancin, vancomycin and daptomycin against 83 enterococcal isolates in planktonic and biofilm states. The MIC90 for vancomycin-susceptible Enterococcus faecalis was 0.125 and 4μg/mL for dalbavancin and daptomycin, respectively. For vancomycin-resistant Enterococcus faecium, the MIC90 was >16 and 2μg/mL for dalbavancin and daptomycin, respectively. Dalbavancin minimum biofilm inhibitory concentrations (MBICs) for vancomycin-susceptible and -resistant isolates were ≤0.25 and >16μg/mL, respectively. The daptomycin MBIC90 for all isolates was 4μg/mL. For E. faecalis and E. faecium, dalbavancin minimum biofilm bactericidal concentrations (MBBCs) for vancomycin-susceptible and -resistant isolates were ≤4 and >16μg/mL, respectively, whereas vancomycin MBBCs were >128μg/mL for all isolates, and daptomycin MBBC90 values for both species were 128μg/mL. In summary, dalbavancin exhibited in vitro activity against all tested isolates of vancomycin-susceptible, but not against vancomycin-resistant enterococci; activity was observed in both the planktonic and biofilm states.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Biofilm; Dalbavancin; Enterococcus

Mesh:

Substances:

Year:  2017        PMID: 29195766     DOI: 10.1016/j.diagmicrobio.2017.09.015

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  11 in total

1.  Population pharmacokinetics of dalbavancin and dosing consideration for optimal treatment of adult patients with staphylococcal osteoarticular infections.

Authors:  Pier Giorgio Cojutti; Matteo Rinaldi; Eleonora Zamparini; Nicolò Rossi; Sara Tedeschi; Matteo Conti; Federico Pea; Pierluigi Viale
Journal:  Antimicrob Agents Chemother       Date:  2021-03-01       Impact factor: 5.191

2.  Evaluation of Non-Tissue Culture- versus Tissue Culture-Treated Microplates for Oritavancin Susceptibility Testing.

Authors:  Qun Yan; Melissa J Karau; Robin Patel
Journal:  J Clin Microbiol       Date:  2018-03-26       Impact factor: 5.948

3.  Safety and Efficacy of Prolonged Use of Dalbavancin in Bone and Joint Infections.

Authors:  L Morata; J Cobo; M Fernández-Sampedro; P Guisado Vasco; E Ruano; J Lora-Tamayo; M Sánchez Somolinos; P González Ruano; A Rico Nieto; A Arnaiz; M Estébanez Muñoz; M E Jiménez-Mejías; A B Lozano Serrano; E Múñez; D Rodriguez-Pardo; R Argelich; A Arroyo; J M Barbero; F Cuadra; A Del Arco; M D Del Toro; L Guio; D Jimenez-Beatty; N Lois; O Martin; R M Martínez Alvarez; F J Martinez-Marcos; L Porras; M Ramírez; J Vergas García; A Soriano
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

Review 4.  Understanding Biofilms and Novel Approaches to the Diagnosis, Prevention, and Treatment of Medical Device-Associated Infections.

Authors:  Yu Mi Wi; Robin Patel
Journal:  Infect Dis Clin North Am       Date:  2018-09-18       Impact factor: 5.982

5.  Real-world experience with dalbavancin therapy in gram-positive skin and soft tissue infection, bone and joint infection.

Authors:  Selma Tobudic; Christina Forstner; Heinz Burgmann; Heimo Lagler; Christoph Steininger; Ludwig Traby; Mathias G Vossen; Stefan Winkler; Florian Thalhammer
Journal:  Infection       Date:  2019-09-13       Impact factor: 3.553

6.  Defining conditions for biofilm inhibition and eradication assays for Gram-positive clinical reference strains.

Authors:  Cristina D Cruz; Shreya Shah; Päivi Tammela
Journal:  BMC Microbiol       Date:  2018-11-03       Impact factor: 3.605

7.  Dalbavancin for treating prosthetic joint infections caused by Gram-positive bacteria: A proposal for a low dose strategy. A retrospective cohort study.

Authors:  L Buzón Martín; M Mora Fernández; J M Perales Ruiz; M Ortega Lafont; L Álvarez Paredes; M A Morán Rodríguez; M Fernández Regueras; M A Machín Morón; G Mejías Lobón
Journal:  Rev Esp Quimioter       Date:  2019-10-22       Impact factor: 1.553

8.  A Dalbavancin Lock Solution Can Reduce Enterococcal Biofilms After Freezing.

Authors:  Marta Díaz-Navarro; Rama Hafian; Irene Manzano; María J Pérez-Granda; Emilia Cercenado; Cristina Pascual; Carmen Rodríguez; Patricia Muñoz; María Guembe
Journal:  Infect Dis Ther       Date:  2022-01-16

Review 9.  Dalbavancin for the Treatment of Prosthetic Joint Infections: A Narrative Review.

Authors:  Luis Buzón-Martín; I Zollner-Schwetz; Selma Tobudic; Emilia Cercenado; Jaime Lora-Tamayo
Journal:  Antibiotics (Basel)       Date:  2021-05-31

10.  DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci.

Authors:  Carmen Hidalgo-Tenorio; David Vinuesa; Antonio Plata; Pilar Martin Dávila; Simona Iftimie; Sergio Sequera; Belén Loeches; Luis Eduardo Lopez-Cortés; Mari Carmen Fariñas; Concepción Fernández-Roldan; Rosario Javier-Martinez; Patricia Muñoz; Maria Del Mar Arenas-Miras; Francisco Javier Martínez-Marcos; Jose Maria Miró; Carmen Herrero; Elena Bereciartua; Samantha E De Jesus; Juan Pasquau
Journal:  Ann Clin Microbiol Antimicrob       Date:  2019-10-19       Impact factor: 3.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.